unit 3: DM meds & treatment regimens Flashcards
DM1 treatment: _______ injections of both ______ & _____ insulin OR ________
DM1 treatment: MULTIPLE DAILY injections of PRANDIAL and BASAL insulin OR pump
DM1 insulin initiation dose in a metabolically stable person
0.5 units/kg/day
DM1 insulin dosing: 1st half ______ insulin to control BG after meals
prandial
DM1 insulin dosing: 2nd half ______ to control BG between meals
basal
______ insulin needs to be VERY individualized
prandial
DM2 treatment initiation med
metformin
DM2 + ASCVD pts treat with ______ or ________
SGLT2 inhibs
OR
GLP-1 receptor agonists
DM2 w high ASCVD risk OR existing HF treat w
SGLT2 inhibs
DM2 + CKD treat with _______ or ________
SGLT2 inhibs
OR
GLP-1 receptor agonists
*reduces risk of DKD progression, CV events or both
DM2. re-eval treatment every?
3-6m
what vitamin deficiency should we check for in DM2? (and maybe DM1? i dk why not?)
vitamin b12
biguanide (1)
metformin
sulfonylureas (5)
nemonic: "3G Text & Call new york areas" Tolbutamide chlorpropamide Glyburide Glimepiride Glipizide
thiazolidinediones (1)
pioglitazone
alpha-glucosidase inhibitors (2)
nemonic: “AGh I AM carb’d out”
acarbose
miglitol
GLP-1 receptor agonists (5)
nemonic: TIDE GETS LITTLE PRICKS (“tides”)(all meds are SQ)
also* “LADLE” for med names
exanatide (byetta) liraglutide (victoza) albiglutide (tanzeum) dulaglutide (trulicity) lixisesatide (adlyxin)
Dpp4-inhibitors (3)
nemonic: Diana Gliptin had 3 SAXAphones SITting in a LINe
saxagliptin
sitagliptin
linagliptin
SGLT-2 inhibs
nemonic: “CAN EMily DAte 2nd sergeant lieutenants?”
canglifozin
empagliflozin
dapagliflozin
metformin class & MOA
- biguanide
2. @ liver: decrease gluconeogenesis & insulin resistance
metformin does or does not require functional beta cells?
DOES NOT
metformin contras:
- contrast dye
- kidney/liver/HF
- eGFR < 46
metformin adverse reaction
lactic acidosis
sulfonylureas MOA
@pancreas: mimics glucose > decrease K+ channels > increase Ca > increase insulin secretion from beta cells of pancreas
do sulfas require functioning beta cells?
YES
TZDs MOA
@nucleus: increase PPAR-gamma > increase insulin sensitivity > decreased insulin resistance
do TZDs require functioning beta cells?
NOPE
alpha-glucosidase inhibs MOA
@intestine: decrease a-glucosidase > decrease glucose absorption > slow absorption of carbs into proximal gut blood after meals
GLP-1 receptor agonists MOA
GLPA (promotes GLP-1 production > GLP -1 > @PANCREAS > increased insulin secretion > decreased glucagon secretion > delays gastric emptying > pt feels less hungy > improves post prandial hyperglycemia
DPP4 - inhibs MOA
DPP4 inhib > stops DPP4 production > stops GLP1 productions > @PANCREAS > increased insulin after meal & decreased glucose made by liver
SGLT-2 inhibs MOA
@proximal renal tubule > SGLT-2 receptor inhib > blocks glucose reuptake from urine > increased renal glucose excretion
Sulfas require dose adjustments when levels of _____ or _____ intake change
activity
OR
caloric intake
TZDs may increase ______ levels
lipid levels
sulfas adverse reaction:
c-peptide ??
hypoglycemia
weight gain
TZD adverse reactions
liver tox
edema/hf
weight gain
fractures
alpha-glucosidase inhibitors adverse reactions
abd pain
dirrhea
farting
elevated liver enzymes
GLP1 receptor agonist adverse reaction:
pancreatitis
DPP4 inhibitors adverse reaction
GI/URI symptoms
pancreatitis
nasopharyngitis
SGLT-2 inhibs adverse reactions
UTI, VV candidiasis, RF, hyperkalemia, dehydrations, hypotension
rapid acting insulin onset, peak, duration
O: 10-15
P: 1-2h
D: 3-5h
short-acting insulin (regular)
O: 30-60
P: 2-4h
D: 4-8h
intermediate acting insulin
O: 1-3h
P: 4-10h
D: 10-18h
long acting insulin drugs (4)
- glargine/lantus
- glargine/tujeo
- detemir
- degludec